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Objective: To evaluate the relationship between initiation of atypical antipsychotic agents and the risk of hyper-
glycemic emergencies.
Method:We conducted amulticentre retrospective cohort study using administrative health data from 7 Canadi-
an provinces and the UK Clinical Practice Research Datalink. Hospitalizations for hyperglycemic emergencies
(hyperglycemia, diabetic ketoacidosis, hyperosmolar hyperglycemic state) were compared between new users
of risperidone (reference), and new users of olanzapine, other atypical antipsychotics, and typical antipsychotics.
We used propensity scores with inverse probability of treatment weighting and proportional hazard models to
estimate the site-speciﬁc hazard ratios of hyperglycemic emergencies in the year following drug initiation sepa-
rately for adults under and over age 66 years. Site-level results were pooled using meta-analytic methods.
Results: Among 725,489 patients, 55% were aged 66+ years; 5% of younger and 19% of older patients had pre-
existing diabetes. Hyperglycemic emergencies were rare (1–2 per 1000 person years), but more frequent in pa-
tients with pre-existing diabetes (6–12 per 1000 person years).We did not ﬁnd a signiﬁcant difference in risk of
hyperglycemic emergencies with initiation of olanzapine versus risperidone; however heterogeneity existed be-
tween sites. The risk of an eventwas signiﬁcantly lowerwith other atypical (99%quetiapine) compared to risper-
idone use in older patients [adjusted hazard ratio, 95% conﬁdence interval (CI): 0.69, 0.53–0.90].
Conclusions: Risk for hyperglycemic emergencies is low after initiation of antipsychotics, but patients with pre-
existing diabetes may be at greater risk. The risk appeared lower with the use of quetiapine in older patients,
but the clinical signiﬁcance of the ﬁndings requires further study.
© 2014 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.6 August 2012, at the 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) in
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Atypical antipsychotic agents are ﬁrst-line therapy for symptoms of
schizophrenia and other psychotic disorders. However, numerous stud-
ies have documented a higher incidence of diabetes and hyperglycemia
among patients treated with atypical antipsychotics (at least partially
attributed to effects of weight gain) compared to typical agents (Caro
et al., 2002; Koller and Doraiswamy, 2002; Kornegay et al., 2002; Koro
et al., 2002; Sernyak et al., 2002; Buse et al., 2003; Gianfrancesco et al.,
2003a, 2003b; Lindenmayer et al., 2003; Citrome et al., 2004; Leslie
and Rosenheck, 2004; Gianfrancesco et al., 2006; Ramaswamy et al.,
2006; DuMouchel et al., 2008; Smith et al., 2008). In addition, case re-
ports and case series have suggested that these drugs may also have
acute hyperglycemic effects, occasionally leading to diabetic
ketoacidosis (DKA), coma, and death (Muench and Carey, 2001;
Roefaro and Mukherjee, 2001; Jin et al., 2002; Koller et al., 2003;
Wilson et al., 2003; Koller et al., 2004; Takahashi et al., 2005; Marlowe
et al., 2007; Kohen et al., 2008; Makhzoumi et al., 2008). However,
these infrequent, but serious adverse effects have been difﬁcult to
quantify.
In a recent population-based study of Ontario seniors, new exposure
to antipsychotic therapy was associated with an increased risk of
hospitalization for hyperglycemia or diabetes among patients with
(Lipscombe et al., 2009) and without pre-existing diabetes (Lipscombe
et al., 2011). In those with diabetes, the strength of the association de-
clined with increasing duration of use (Lipscombe et al., 2009). While
these ﬁndings are suggestive of acute metabolic effects, the studies
had insufﬁcient power to isolate the risk of life-threatening hyperglyce-
mic emergencies, such asDKA, from that of diabetes. In addition, contro-
versy exists regarding whether the risk of hyperglycemia varies
depending on the type of antipsychotic agent. There is some evidence
that olanzapine may be associated with a higher risk than risperidone
(Ramaswamy et al., 2007), but data are limited.
The Canadian Network for Observational Drug Effect Studies
(CNODES) (Suissa et al., 2012), a newly-formed collaboration of eight in-
dependent research teams with access to administrative data provides a
unique opportunity to study these rare but important effects. According-
ly, we used the healthcare records of over 725,000 patients to quantify
the association between new treatment with different antipsychotic
agents and hospitalization for an acute hyperglycemic emergency.
2. Method
2.1. Setting and source population
We used a common analytical protocol to conduct the study in seven
Canadian provinces (British Columbia, Alberta, Saskatchewan,Manitoba,
Ontario, Quebec, and Nova Scotia), with a total source population of
approximately 34 million, and the United Kingdom General Practice
Research Database (GPRD, since renamed Clinical Practice Research
Datalink or CPRD), which contains health records for approximately
12 million residents. The study population consisted of patients aged
18 years or older who were newly treated with an antipsychotic medi-
cation between April 1, 1997 and March 31, 2010. In three provinces
(Nova Scotia, Ontario, and Alberta), drug exposure data were available
only for patients aged 65 years and older.
2.2. Data sources
All Canadian centres contributed information from their respective
provincial administrative health care databases. Prescription drug
claims included patient-level records specifying, at minimum, the
name and quantity of eachmedication and the date that themedication
was dispensed. Physician service claims and hospitalization records in-
cluded the date of each service encounter or admission, 1 to 25 Interna-
tional Classiﬁcation of Disease (ICD)-9 or ICD-10 diagnosis codes, andphysician service or hospital procedure codes, as appropriate. The
GPRD captures drug prescriptions (rather than dispensations), and sev-
eral data elements not available in the Canadian databases, including
laboratory test results, body mass index, and smoking status. All of the
databases have been used extensively in observational research.
2.3. Cohort creation
In each jurisdiction, patients from the source population were in-
cluded in the cohort if they were newly dispensed an antipsychotic
medication between April 1, 1998 (or one year after the beginning of
data availability) and March 31, 2010. New exposure was deﬁned as
no prescription for an antipsychotic in the preceding 365 days. The
date of the ﬁrst new exposure during the study period was deﬁned as
the cohort entry date.
Patients were excluded if, on the cohort entry date, they were less
than 18 years of age (or 66 years of age in the provinces where drug
beneﬁt coverage started at age 65), had fewer than 365 days of enroll-
ment in their health plan, resided in a nursing home, or received more
than one antipsychotic medication. Patients also were excluded if they
were hospitalized with the primary study outcome within 30 days pre-
ceding cohort entry, were hospitalized for greater than 30 consecutive
days in the year preceding cohort entry, or received renal dialysis or pal-
liative care in the year preceding cohort entry.
2.4. Exposure deﬁnition
Drug exposure was determined at cohort entry based upon the ﬁrst
antipsychotic medication received — i.e., all analyses were based on an
intention-to-treat principle. The reference exposure was risperidone,
as it was themost frequently used antipsychotic and is thought to be as-
sociated with a lower risk of hyperglycemia (Ramaswamy et al., 2007).
The other exposure groupswere: olanzapine, the remaining atypical an-
tipsychotics collectively, and all remaining ‘typical’ antipsychotics (e.g.,
haloperidol, phenothiazines). The speciﬁc agents, routes, and corre-
sponding Anatomical Therapeutic Chemical (ATC) classiﬁcations are
listed in Appendix 1.
2.5. Deﬁnition of the primary outcome measure: hyperglycemic emergency
We deﬁned a hyperglycemic emergency as the ﬁrst hospital admis-
sion in the 365 days followingdrug initiation (cohort entry) thatwas as-
sociated with a pre-admission diagnosis of hyperglycemia, DKA, or
hyperglycemic hyperosmolar state (HHS) using the ICD-9 and ICD-10
diagnosis codes listed in Appendix 2. In all analyses the date of hospital
admission served as the outcome event date.
2.6. Statistical analysis
Our analyses comprised one primary and two secondary pair-wise
comparisons of the risk of a hyperglycemic emergency,with risperidone
serving as the reference group throughout. Due to evidence of greater
weight gain and diabetes risk with olanzapine (Allison and Casey,
2001; Ramaswamy et al., 2007), the primary comparator was
olanzapine. The secondary comparisons were with other atypical anti-
psychotics and typical antipsychotics, respectively.
In each comparison, we employed inverse probability of treatment
weighting (IPTW) using a propensity score to estimate marginal treat-
ment effects (Austin, 2011). The propensity score represented the pre-
dicted probability of treatment with the comparator antipsychotic
(versus risperidone) based upon a set of baseline patient characteristics
thatwe believed could inﬂuence the risk of a hyperglycemic emergency.
Propensity scores were estimated using logistic regression models in
which treatment with the comparator antipsychotic was regressed
on age, sex, and the following pre-speciﬁed covariates: calendar year
of cohort entry; history of diabetes, schizophrenia, and dementia;
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(Schneeweiss et al., 2001); number of hospitalizations, outpatient fam-
ily physician consultations and outpatient psychiatric consultations in
the year preceding cohort entry; and concurrent exposure to selected
drugs that are markers of disease or could inﬂuence glucose control.
The CPRD team added smoking status, alcohol consumption, and body
mass index.
We estimated the absolute difference in the probability of a hyper-
glycemic emergency within 365 days of drug initiation. To estimate
the effect of the comparator antipsychotic agent versus risperidone,
the cause-speciﬁc hazard for the comparator was estimated by using a
Cox proportional hazards regression model to regress the hazard of
the adverse event on treatment status. The analysis incorporated the
IPT weights and used a robust variance estimator. In order to estimate
the cause-speciﬁc hazard, which is of etiological interest, subjects
were censored on the occurrence of death. Treatment effects were esti-
mated separately for patients aged 18–65 years and 66 years and older,
as well as within each age group for the subset of patients with pre-
existing diabetes.
All analyses were carried out independently at each study site, with
each site remaining blinded to results from other sites until the ﬁndings
were pooled. Meta-analyses were performed independently by a team
member not involved in the site-level analyses (RP) using ﬁxed-effect
models with inverse variance weighting. The magnitude of between-
site heterogeneity was estimated using the I2 statistic (Higgins and
Thompson, 2002). In a sensitivity analysis, the results were pooled
using random-effects models.2.7. Secondary analysis
To address concerns regarding treatment discontinuation and
switches that would not be incorporated in our intention-to-treat
analysis, we also performed a secondary analysis using a nested case–
control analysis of our cohort. Cases were deﬁned as subjects at risk of
a hyperglycemic event, and were matched 5:1 on age, sex, calendar
year, pre-existing diabetes, and schizophrenia, to controls who did not
experience a hyperglycemic event. The event date served as the index
date for the cases, and controls were assigned index dates of their
matched cases. Antipsychotic exposure was deﬁned based on the most
recent prescription dispensed prior to the index date. A conditional lo-
gistic regression model was used to estimate the odds ratio for the ad-
verse event, comparing the comparator agent to risperidone, after
adjusting for the Romano index.Table 1
Number of patients and crude hyperglycemic emergency event rates according to age group, s
Characteristic Number of patients (% column total)
Age 18–65 years Age 66+ years
Sex
Male 154,095 (47.5) 158,132 (39.4)
Female 170,417 (52.5) 242,845 (60.6)
Diabetes
Yes 16,793 (5.2) 75,970 (18.9)
No 307,719 (94.8) 325,007 (81.1)
Study site
Nova Scotia – 12,702 (3.2)
Quebec 108,923 (33.6) 102,419 (25.5)
Ontario – 154,695 (38.6)
Manitoba 27,066 (8.3) 12,109 (3.0)
Saskatchewan 20,179 (6.2) 20,524 (5.1)
Alberta – 26,557 (6.6)
British Columbia 141,835 (43.7) 50,470 (12.6)
GPRD 26,509 (8.2) 21,501 (5.4)
Overall 324,512 400,977
CI: conﬁdence interval.
GPRD: General Practice Research Database.3. Results
3.1. Characteristics of subjects and exposures
The study involved 725,489 patients, 55% aged 66 years or older
(Table 1). Five jurisdictions contributed to analyses of patients
aged 18–65 years, most (75%) of whom resided in Quebec and British
Columbia. Four of these sites had a sufﬁcient number of patients to par-
ticipate in the subgroup analyses involving patients with pre-existing
diabetes. All eight sites contributed to analyses of older patients, two-
thirds of whom resided in Quebec and Ontario, Canada's most populous
provinces. Six of these sites participated in the subgroup analyses of di-
abetic patients. Forty-eight percent of the younger cohort wasmale and
5% had diabetes, compared with 39% and 19%, respectively, among the
older patients.
Table 2 gives the distribution of study patients by initial drug thera-
py and age group. Twenty-four percent of younger patients received the
reference drug, risperidone, compared with 39% of older patients. (Of
note, in Canada, only risperidone has an approved indication for man-
agement of behavioural symptoms of dementia (BPSD) (Janssen Inc.,
2013).) In contrast, 38% of younger patients and 19% of older patients
received other atypical agents, which was quetiapine in 98.7% of those
18–65 years and 99.6% of those 66 years and older. Olanzapine was
used in 15% and 13% of younger and older patients respectively.3.2. Acute hyperglycemic emergency rates
Therewere 892 events reported overall amongnewusers of antipsy-
chotics: 283 events in patients aged 18–65 years; and 609 events in pa-
tients aged 66 years and older. In general, hyperglycemic emergencies
were rare, ranging from approximately 1 per 1000 person years in pa-
tients aged 18–65 years to about 2 per 1000 person years in patients
aged 66 years and older (Table 1). In those with pre-existing diabetes
compared to those without, the rate of hyperglycemic emergencies
was 8-fold higher (6.6 versus 0.85 per 1000 person years) among
older patients, and 30-fold (11.5 versus 0.39 per 1000 person years)
among patients age 18–65 years. In patients aged 18–65 years, 59.4%
of events were admissions for DKA, 9.6% were for HHS, and 30.9%
were for hyperglycemia. In contrast, these events were observed at sim-
ilar frequencies among those aged 66 years and older (i.e., 29.4%, 33.7%,
and 37.4%, respectively).
Overall, there was relatively little variation in crude event rates
among the individual drug exposure groups (Table 2). Variationex, diabetes status, and study site.
Number of events (and crude event rate per 1000 person years, 95% CI)
Age 18–65 years Age 66+ years
132 (0.92, 0.76–1.07) 273 (2.30, 2.03–2.57)
151 (0.95, 0.80–1.10) 336 (1.70, 1.52–1.88)
172 (11.49, 9.78–13.21) 389 (6.64, 5.98–7.30)
111 (0.39, 0.31–0.46) 220 (0.85, 0.74–0.97)
– 13 (1.38, 0.63–2.14)
95 (0.94, 0.79–1.18) 157 (2.03, 1.71–2.35)
– 301 (2.34, 2.07–2.60)
31 (1.21, 0.78–1.63) 9 (0.98, 0.34–1.62)
25 (1.29, 0.78–1.79) 35 (2.10, 1.41–2.80)
– 25 (1.30, 0.79–1.81)
110 (0.80, 0.65–0.95) 51 (1.19, 0.86–1.52)
22 (0.95, 0.55–1.34) 18 (1.38, 0.74–2.02)
283 (0.93, 0.82–1.04) 609 (1.92, 1.77–2.08)
Table 2
Number of patients and crude hyperglycemic emergency event rates according to age group and drug exposure.
Drug exposure Number of patients (% column total) Crude event ratea (per 1000 person years, 95% CI)
Age 18–65 years Age 66+ years Age 18–65 years Age 66+ years
Risperidone 76,212 (23.5) 158,019 (39.4) 0.78, 0.58–0.99 2.01, 1.77–2.26
Olanzapine 47,699 (14.7) 52,351 (13.1) 0.85, 0.58–1.13 1.87, 1.46–2.27
Other Atypical 123,971 (38.2) 75,514 (18.8) 0.93, 0.75–1.10 1.61, 1.30–1.93
Typical 76,630 (23.6) 115,091 (28.7) 1.03, 0.80–1.27 2.06, 1.75–2.37
Overall 324,512 400,977 0.93, 0.82–1.04 1.92, 1.77–2.08
CI: conﬁdence interval.
a Rates are estimated based on event counts by exposure status, whereby suppressed small cells were assigned a value of 3.
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status (Table 3), where the drug-speciﬁc rates ranged from 5 to 14
per 1000 person years in those with diabetes versus 0.3 to 1 per
1000 person years in those without diabetes.
3.3. Comparative analyses
Based on ﬁxed-effect meta-analyses, relative to new users of risper-
idone, there was no signiﬁcant increase in risk of hyperglycemic emer-
gencies among new users of our primary comparator, olanzapine,
regardless of age or diabetes status (Table 4). Results were similar for
typical antipsychotics in both age groups. However, other atypical
agents (99% quetiapine) were associated with a signiﬁcantly lower
risk than risperidone in patients over age 66 years (adjusted hazard
ratio [HR], 95% conﬁdence interval [CI]: 0.69, 0.53–0.90). In older pa-
tients with pre-existing diabetes, both typical antipsychotics and other
atypical antipsychotics were associated with a lower risk than risperi-
done (adjustedHR, 95% CI: 0.62, 0.41–0.95; and 0.68, 0.49–0.95; respec-
tively). Site level results are presented in Web Figs. 1–12. Whereas
ﬁndings were homogeneous across sites for the majority of our meta-
analyses, signiﬁcant heterogeneity existed for the analysis of olanzapine
versus risperidone in older patients, both overall and in those with pre-
existing diabetes (I2 = 49%, p = 0.07 and I2 = 64.4%, p = 0.02 respec-
tively; Web Figs. 7 and 8). Meta-analyses using random effects models
gave similar results. There were no statistical differences in outcomes
between current use of olanzapine, other atypical, or typical agents
compared to current use of risperidone onmeta-analyses of our second-
ary nested case–control analyses. However, power was limited as some
sites could not contribute asmodels did not converge due to small num-
bers (data not shown).
4. Discussion
In this study of over 725,000 patients newly exposed to antipsychot-
ic medication, hyperglycemic emergencies were uncommon (in the
range of 1–2 events per 1000 person years of exposure), but were rela-
tively more frequent among those with pre-existing diabetes, in whom
event rates approached 12 per 1000 person years. Despite prior evi-
dence of potential higher risks of diabetes and hyperglycemia with
olanzapine (Ramaswamy et al., 2006; Ramaswamy et al., 2007), in ourTable 3
Crude hyperglycemic emergency event rates according to age group, diabetes status, and drug
Drug exposure Crude event ratea (per 1000 person years, 95% CI)
Age 18–65 years
Diabetes (n = 16,793) No diabetes (n = 307
Risperidone 9.45, 6.32–12.59 0.36, 0.22–0.50
Olanzapine 9.62, 4.90–14.33 0.51, 0.30–0.73
Other Atypical 11.71, 9.01–14.41 0.30, 0.20–0.41
Typical 14.20, 10.23–18.18 0.46, 0.30–0.63
Overall 11.49, 9.78–13.21 0.39, 0.31–0.46
CI: conﬁdence interval.
a Rates are estimated based on event counts by exposure status, whereby suppressed smalllarge population-based sample we failed to ﬁnd a signiﬁcant increase
in hyperglycemic emergencies among new olanzapine versus risperi-
done users, regardless of age or diabetes status. In contrast, older per-
sons treated with other atypical antipsychotics (mainly quetiapine)
experienced about 30% fewer events than those exposed to risperidone.
Our ﬁndings highlight the importance of glucose monitoring in seniors
initiating antipsychotic therapy, and suggest the need for further re-
search to conﬁrm the relative safety advantage with quetiapine.
While a link between antipsychotic treatment and hyperglycemia is
well documented, prior studies have focused mainly on younger pa-
tientswith schizophrenia,whomay have a higher baseline risk of diabe-
tes (Dixon et al., 2000). This association has made it difﬁcult to separate
the effects of the medication from those of the disease itself. Further,
previous studies of seniors have been too small to demonstrate differ-
ences among individual medications, or to consider acute effects in
the period immediately following treatment initiation. Indeed, evidence
suggests that the majority of hyperglycemic emergencies occur in the
ﬁrst six months of antipsychotic therapy (Jin et al., 2002; Lipscombe
et al., 2009). By restricting our analyses to newusers, our studymore ac-
curately reﬂects the experience of patients and risks most likely attrib-
utable to antipsychotic therapy. By not doing so, one runs the risk of
underestimating harms by including longer-term users who are less
susceptible to adverse outcomes (Moride and Abenhaim, 1994).
Generally, prior studies among patients with schizophrenia have
suggested greater metabolic risks with olanzapine (Ramaswamy et al.,
2006, 2007) or atypical agents collectively (Smith et al., 2008) com-
paredwith typical antipsychotics. However, bias due to greater baseline
risk of diabetes cannot be excluded in these studies, and evidence is un-
clear in older patients treated primarily for BPSD (Lipscombe et al.,
2009, 2011). Our large study acrossmultiple databases failed to demon-
strate a signiﬁcant increase in risk for hyperglycemic emergencies with
olanzapine in younger or older patients. However, we did note substan-
tial heterogeneity across sites for the comparison of olanzapine and ris-
peridone in older patients. While some sites found a higher risk of
hyperglycemic emergencies with olanzapine, the two largest sites con-
tributing the greatest weight to themeta-analysis (Quebec andOntario)
reportedhazard ratios close to unity (Web Figs. 7 and 8). The reasons for
these differences are unclear. However, differences in provincial reim-
bursement policiesmayhave been a contributing factor.Whereas no re-
strictions exist in Ontario and Quebec, the provincial drug beneﬁtexposure.
Age 66+ years
,724) Diabetes (n = 75,970) No diabetes (n = 325,007)
7.07, 6.00–8.14 0.85, 0.67–1.02
6.74, 4.90–8.57 0.78, 0.49–1.08
4.98, 3.76–6.20 0.67, 0.45–0.90
7.35, 5.95–8.76 1.03, 0.79–1.27
6.64, 5.98–7.30 0.85, 0.74–0.97
cells were assigned a value of 3.
Table 4
Summary of the results of the ﬁxed-effect meta-analyses.a
Drug exposure Age 18–65 years Age 66+ years
Overall Diabetes Overall Diabetes
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Risperidone 1.00 – 1.00 – 1.00 – 1.00 –
Olanzapine 1.15 0.71–1.86 1.19 0.52–2.72 1.13 0.87–1.48 1.12 0.80–1.56
Other Atypical 0.94 0.64–1.38 0.89 0.45–1.68 0.69 0.53–0.90 0.68 0.49–0.95
Typical 0.95 0.61–1.54 1.09 0.61–1.95 1.03 0.73–1.45 0.62 0.41–0.95
HR: hazard ratio.
CI: conﬁdence interval.
a Adjusted for: age; sex; calendar year of cohort entry; history of diabetes, schizophrenia and dementia; neighbourhood income quintile; Romano Comorbidity Index; number of
hospitalizations, outpatient family physician consultations and outpatient psychiatric consultations in the year preceding cohort entry; and concurrent exposure to selected drugs that
are markers of disease or could inﬂuence glucose control.
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inces that reported increased risks) pay for olanzapine only when pre-
scribed as second-line therapy. One might speculate that such patients
are more vulnerable to decompensated glucose control due to untreat-
ed behavioural symptoms, thereby introducing a selection bias within
these provinces. By examining this question across several health care
settings simultaneously, our study was able to expose this potential
bias and avoid misinterpretation that may have occurred in a single-
centre study. These ﬁndings argue against a true relative increased
risk of hyperglycemic emergencies with olanzapine, and highlight the
possibility that selection bias may have contributed to an apparent in-
creased risk in prior studies. The interpretation of these ﬁndings is lim-
ited by the heterogeneity of reimbursement policies across provinces,
and further studies are needed.
In our study, the lowest risk of hyperglycemic emergencies was
found in those patients treated with quetiapine (or rarely other newer
atypical antipsychotics). While case reports have documented hyper-
glycemic events following quetiapine treatment (Koller et al., 2004;
Takahashi et al., 2005; Marlowe et al., 2007), further research is needed
to conﬁrm whether quetiapine is in fact metabolically safer than other
atypical agents. Meanwhile, quetiapine may be favoured over other
agents when other clinical indications are similar in patients with in-
creased risk for hyperglycemia.
Despite adjustment for multiple known and suspected confounders,
we acknowledge that there is potential for residual confounding in our
ﬁndings. For example, relative to patients with diabetes who received
risperidone, those prescribed quetiapine may have had fewer unmea-
sured underlying risk factors for hyperglycemia or better adherence to
their diabetes medications. We attempted to address these concerns
by conﬁning our analyses to newusers of antipsychotics amongpatients
who were likely to be receiving the medications for similar indications.
Second, we limited our outcome to hospital visits for hyperglycemic
emergencies, which are likely to be largely non-discretionary and for
which coding quality should be good (Bobo et al., 2011). Third, to help
control for effects of important factors such as dementia, schizophrenia,
and diabetes severity, we adjusted for treatment characteristics at base-
line. Nevertheless, as risperidone is the only antipsychotic with an ap-
proved indication for BPSD (Janssen Inc., 2013), selection biases could
favour some agents. However, that we observed relatively better out-
comes among both users of other atypical agents and older typical
agents argues against important biases. Given that we were only able
to capture drug use in the year before study entry, we could not deter-
minewhether somepatients hadmore remote previous exposure to an-
tipsychotic agents. Our ﬁndings also do not apply to patients taking
multiple antipsychotic agents. Finally, despite the large size of our
study, power remains a limitation, as the 95% conﬁdence intervals for
many analyses include clinically important beneﬁts and harms.
In sum, our large, multicentre study found hyperglycemic emergen-
cies to be rare after initiating antipsychotic therapy, although patients
with diabeteswere at relatively greater risk. Compared to older patients
treated with risperidone, hyperglycemic emergencies may be lessfrequent with quetiapine. While our ﬁndings require replication, they
highlight the importance of glucose monitoring in seniors initiating an-
tipsychotic therapy, particularly in those with pre-existing diabetes.Role of funding source
This study was carried out by the Canadian Network for Observational Drug Effect
Studies (CNODES), a collaborating centre of the Drug Safety and Effectiveness Network
(DSEN), funded by the Canadian Institutes of Health Research (Grant Number DSE-
111845). Lorraine Lipscombe and Kristian Filion are supported by CIHR New Investigator
awards. Peter Austin is supported by a Career Investigator award from the Heart and
Stroke Foundation. Lucie Blais holds an AstraZeneca Research Chair in Respiratory Health.
David Blackburn's position was created through the unrestricted ﬁnancial support of
AstraZeneca Canada, Merck Frosst Canada, Pﬁzer Canada, and the Province of
Saskatchewan's Ministry of Health. Lauren Bresee was supported by the 4th ICPC/
HSFC/CCS Fellowship in Preventive Cardiology and a fellowship award from Alberta Inno-
vates–Health Solutions. Robert Platt is supported by a Chercheur-national award from the
Fonds de la Recherche du Québec–Santé.Contributors
All authors contributed to and have approved the ﬁnal manuscript.
L. Lipscombe — conceptualized and designed the study, conducted the literature
review, wrote the manuscript.
P. Austin — contributed to the study design, developed the analytic plan, edited and
approved the manuscript.
S. Alessi-Severini — contributed to the study design, directed data collection and
analysis at Manitoba site, edited and approved the manuscript.
D. F. Blackburn— contributed to the study design, directeddata collection and analysis
at Saskatchewan site, edited and approved the manuscript.
L. Blais — contributed to the study design, directed data collection and analysis at
Quebec site, edited and approved the manuscript.
L. Bresee — contributed to the study design, directed data collection and analysis at
Alberta site, edited and approved the manuscript.
K.B. Filion— contributed to the study design, directed data collection and analysis for
CPRD database, edited and approved the manuscript.
Y. Kawasumi — contributed to the study design, directed data collection and analysis
at British Columbia site, edited and approved the manuscript.
P. Kurdyak— contributed to the conceptualization of the study, literature review, and
study design, edited and approved the manuscript.
R.W. Platt — contributed to the study design and analytic plan; performed the
meta-analyses, edited and approved the manuscript.
H. Tamim — contributed to the study design, directed data collection and analysis at
Nova Scotia site, edited and approved the manuscript.
J.M. Paterson — contributed to the study design, directed data collection and analysis
at Ontario site, prepared tables and co-wrote manuscript.
The CNODES Investigators— supported the overall design and execution of the study,
provided support for the study, and approved the manuscript.Conﬂict of interest
Ethics approval was obtained from the research ethics board of the university or hos-
pital to which each participating research team is afﬁliated. The following authors report
no competing interests: Lorraine Lipscombe, Michael Paterson, Peter Austin, Lauren
Bresee, Kristian Filion, Yuko Kawasumi, Hala Tamim, and Robert Platt. Silvia Alessi-
Severini reports receiving an unrelated unrestricted research grant from Pﬁzer. David
Blackburn reports his position was created through the unrestricted ﬁnancial support of
AstraZeneca Canada, Merck Frosst Canada, Pﬁzer Canada, and the Province of
Saskatchewan's Ministry of Health. Lucie Blais reports receiving unrelated research grants
from AstraZeneca, Pﬁzer, Sanoﬁ-Aventis, Novartis and Merck Frosst. She also holds an
AstraZeneca Research Chair in Respiratory Health.
59L.L. Lipscombe et al. / Schizophrenia Research 154 (2014) 54–60Acknowledgements
This study was made possible through data sharing agreements between CNODES
member research centres and the respective provincial governments of Alberta, British
Columbia, Manitoba, Nova Scotia, Ontario, Quebec, and Saskatchewan. The opinions, re-
sults, and conclusions reported in this paper are those of the authors. No endorsement
by the provinces is intended or should be inferred.We acknowledge the important contri-
butions of the CNODES analystswhowere involved in this study: Alomgir Hossain, Richard
Morrow, Rick Chin, Sophie Dell'Aniello, Matthew Dahl, Steve Doucette, Yan Wang,
Fangyun Wu, and Amélie Forget.
Appendix 1. Category, name, WHO ATC code, and route of study
antipsychotic agentsName WHO ATC code Route
Atypical
Risperidone (reference) N05AX08 Oral or IM (long-acting)
Olanzapine N05AH03 Oral or IM (short-acting)
Clozapine N05AH02 Oral
Quetiapine N05AH04 Oral
Ziprasidone N05AE04 Oral
Paliperidone N05AX13 Oral
Aripiprazole N05AX12 Oral
Typical
Chlormezanone M03BB02 Oral
Chlorpromazine N05AA01 Oral or IM
Chlorprothixene N05AF03 Oral
Flupenthixol N05AF01 Oral or IM (long-acting)
Fluphenazine N05AB02 Oral or IM (long-acting)
Fluspirilene N05AG01 IM (short-acting)
Haloperidol N05AD01 Oral or IM (short- and
long-acting)
Levomepromazine/
Methotrimeprazine
N05AA02 Oral or IM (short-acting)
Loxapine N05AH01 Oral or IM (short-acting)
Mesoridazine N05AC03 Oral
Perphenazine N05AB03 Oral or IM (short-acting)
Pimozide N05AG02 Oral
Pipotiazine N05AC04 Oral or IM (short-acting)
Tetrabenazine N07XX06 Oral
Thiopropazate N05AB05 Oral
Thioproperazine N05AB08 Oral or IM (short-acting)
Thioridazine N05AC02 Oral
Thiothixene N05AF04 Oral
Triﬂuoperazine N05AB06 Oral
Zuclopenthixol N05AF05 Oral or IM (long-acting)
ATC: Anatomical Therapeutic Chemical classiﬁcation; IM: intramuscular; WHO: WorldAppendix 2. Diagnosis codes for hyperglycemic emergencies
Health Organization.Endpoint ICD-9 ICD-10
Hyperglycemia 790.29 R739
Diabetes ketoacidosis (DKA) 250.10, 250.11, 250.12,
250.13
E10.1, E11.1, E13.1,
E14.1
Hyperosmolar hyperglycemic 250.20, 250.21, 250.22, E11.0, E13.0, E14.0
state (HHS) 250.23Appendix 3. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.schres.2014.01.043.References
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